Company news

Alnylam Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022

November 30, 2022

Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year

October 26, 2022

Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

October 26, 2022

Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results

October 12, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

October 5, 2022

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting

September 29, 2022

Alnylam Announces New Management Appointments

September 20, 2022

Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

September 19, 2022

Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series

September 18, 2022

Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

September 14, 2022

Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

September 14, 2022

Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022

September 12, 2022

Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes

September 12, 2022

Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes

September 11, 2022

Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

September 7, 2022

Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

August 28, 2022

Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors

August 23, 2022

Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis

August 17, 2022

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

August 2, 2022

Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators

August 1, 2022

Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

July 27, 2022

Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity

July 26, 2022

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

July 21, 2022

Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results

July 17, 2022

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

June 12, 2022

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

June 8, 2022

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

June 1, 2022

Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues

June 1, 2022

Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

May 23, 2022

Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran

May 22, 2022

Alnylam to Webcast Presentations at Upcoming May Investor Conferences

May 3, 2022

Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity

April 27, 2022

Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results

April 13, 2022

Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors

April 4, 2022

Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran

April 3, 2022

Alnylam to Webcast Presentation at Stifel 2022 CNS Days

March 21, 2022

Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna

March 16, 2022

Alnylam Issues 2021 Corporate Responsibility Report

March 15, 2022

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1

February 28, 2022

Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)

February 27, 2022

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity

February 9, 2022

Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference

February 7, 2022

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results

January 23, 2022

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

January 20, 2022

Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

January 13, 2022

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates

January 8, 2022

Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function

January 5, 2022

Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President

January 3, 2022

Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 89 decks. Every deck is listed under its year.